Skip to content

BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019
76.03 -2.15 -2.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 78.10 -0.10%
After-hours 76.03 0.00%
90.1763.3076.032026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BBIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +4.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 10.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 95.8% Better than 98%
Operating margin -100.0% Better than 7%
Net margin -144.4% Better than 6%
Return on equity -192.4% Better than 3%
Return on invested capital -78.6% Better than 3%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -6.7% Better than 58%
6-month return 10.0% Better than 72%
12-month return (ex latest month) 0.0% Better than 33%
Distance below 52-week high 18.6% Better than 63%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.8x Better than 70%
Debt to assets 199.0% Better than 0%
Interest coverage -3.1x Better than 18%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 94.4% Better than 77%
Upside to average target 44.3% Better than 62%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.90%
1M +12.55%
3M -8.33%
6M +11.45%
YTD -0.60%
1Y +17.66%
3Y +160.02%
5Y +78.26%

Key statistics

Price & volume

Prev close
78.18
Open
77.85
Day range
75.46 - 78.24
Avg price
76.44
Volume
1.48M
Turnover
113.03M
Amplitude
3.56%
52-week range
62.50 - 93.42

Valuation

P/E
-20.11
P/E (TTM)
-25.09
P/B
-5.69
EPS
-3.78
Net profit
-736.35M
Net assets
-2.60B

Share structure

Market cap
14.81B
Float cap
12.39B
Shares out
194.80M
Float shares
163.01M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-06-27
52-week range 44% of range
62.50 93.42

18.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+104.47M net over the window

Short interest

Shares short
20.85M
As of
2026-10-30

Frequently asked questions

What is the current stock price of BridgeBio Pharma (BBIO)?

BridgeBio Pharma last traded at 76.03. This page shows a periodic quote snapshot. Check the displayed quote time.

What is BridgeBio Pharma's market cap?

About 14.81B.

What is the P/E ratio of BridgeBio Pharma?

The trailing twelve-month P/E is -25.09. The Valuation tab shows it against the stock's own five-year range.

Does BridgeBio Pharma pay a dividend?

BridgeBio Pharma does not currently pay a regular dividend.

Is BridgeBio Pharma a buy according to analysts?

The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 109.69, which implies 44.3% upside from the current price. This is not investment advice.

What is BridgeBio Pharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates BridgeBio Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.

BridgeBio Pharma discussion 0 comments

Add a comment